Catheter ablation worked better than drugs for periodic atrial fibrillation / American Heart Association

Catheter ablation worked better than drugs for periodic atrial fibrillationAmerican Heart Association Late-Breaking Clinical Trial Report - Abstract: 18473 - EMBARGOED UNTIL 12:30PM ET
November 14, 2011

Study Highlights:
•High frequency radio waves that destroy electrical triggers in the heart (a treatment called radiofrequency ablation) worked as well as or better than drugs to treat patients with periodic erratic heartbeats.
•Episodes of erratic heartbeats in the heart’s upper chambers, called paroxysmal atrial fibrillation, were less frequent in patients who underwent the ablation procedure.

ORLANDO, FLA., Nov. 14, 2011 —  Catheter ablation, which uses high frequency radio waves to destroy electrical triggers in the heart, worked as well as or better than drugs to reduce periodic episodes of erratic heartbeats in patients with atrial fibrillation, according to late-breaking research presented at the American Heart Association’s Scientific Sessions 2011.

Atrial fibrillation (AF) occurs when the heart’s two upper chambers beat erratically. In one form of the condition, paroxysmal AF, patients have bouts of erratic beats that begin spontaneously and usually last less than a week. Anti-arrhythmic medications can control the heart rhythm and symptoms of AF, but many patients don’t respond well. Atrial fibrillation can lead to serious adverse events such as clots travelling from the heart to obstruct arteries supplying the brain (causing strokes) or other parts of the body causing tissue damage.

Another option for stabilizing the heartbeat is delivering high frequency alternating current through a catheter to destroy the small bits of heart tissue that cause AF. In this case, researchers targeted tissue surrounding the pulmonary veins. This treatment option has not previously been tested for patients who haven’t tried drug treatment.
Researchers randomized participants to either radiofrequency ablation (146) or an anti-arrhythmic drug (148). They assessed the patients at the study’s start, and at 3, 6, 12, 18 and 24 months.

Each time, patients wore a portable heart monitor for seven days. Significant findings included:
•At 3, 6, 12 and 18 months, there was no significant difference in the amount of time patients in the two groups experienced AF (AF burden) nor in the cumulative AF burden.
•At 24 months, the ablation group did have significantly less AF burden than the drug-treated patients.
•Twenty-two radiofrequency ablation patients (15 percent) had AF compared to 43 (29 percent) treated with drugs.
•Ten ablation patients (7 percent) had symptomatic AF episodes compared to 24 (16 percent) in the drug group.
“Ablation therapy is at least as good and tends to be better than drug therapy at preventing episodes of atrial fibrillation,” said Jens Cosedis Nielsen, M.D., lead researcher and professor of cardiology at Aarhus University Hospital in Denmark.

Of the patients primarily treated with ablation, 13 needed supplementary drugs and 54 patients who didn’t improve with drugs underwent supplementary radiofrequency ablation.
“Not every patient should be offered ablation, but this research should be discussed with patients when a physician feels it is a viable treatment option,” Nielsen said.
      Co-authors are Arne Johannesen, M.D., D.M.Sci.; Pekka Raatikainen, M.D.; Gerhard Hindricks, M.D.; Håkan Walfridsson, M.D.; Ole Kongstad, M.D.; Steen Pehrson, M.D., D.M.Sci.; Anders Englund, M.D.; Juha Hartikainen, M.D.; Leif Spange Mortensen, M.S.; and Peter Steen Hansen, M.D., D.M.Sci.

      Disclosures are here: http://newsroom.heart.org/pr/aha/document/Disclosures_for_LBCT.xlsx.
      Biosense Webster, Inc., and the Danish Heart Foundation funded the study.

###
Statements and conclusions of study authors that are presented at American Heart Association scientific meetings are solely those of the study authors and do not necessarily reflect association policy or position. The association makes no representation or warranty as to their accuracy or reliability. The association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific association programs and events.  The association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and device corporations are available at www.heart.org/corporatefunding .

CONTACT:
AHA News Media in Dallas: (214) 706-1396
AHA News Media Office, Nov. 12–16, at the
Orange County Convention Center: (407) 685-5410
For public inquiries: (800) AHA-USA1 (242-8721)

Catheter ablation worked better than drugs for periodic atrial fibrillation / American Heart Association